...
首页> 外文期刊>DNA and Cell Biology >CpG Array Analysis of Histone H3 Lysine 4 Trimethylation in Peripheral Blood Mononuclear Cells of Uremia Patients
【24h】

CpG Array Analysis of Histone H3 Lysine 4 Trimethylation in Peripheral Blood Mononuclear Cells of Uremia Patients

机译:尿毒症患者外周血单个核细胞中组蛋白H3赖氨酸4三甲基化的CpG阵列分析

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Studies of the epigenome have attracted little interest in nephrology, especially in uremia. Several lines of evidence have suggested that there are links between genomic DNA hypomethylation and cardiovascular complications in uremia patients. However, to date, our knowledge about the alterations in histone methylation in uremia is unknown. H3K4me3 variations were analyzed in peripheral blood mononuclear cells from 20 uremia patients and 20 healthy subjects, using chromatin immunoprecipitation microarray (ChIP-chip) approach. ChIP-real-time polymerase chain reaction (PCR) was used to validate the microarray results. mRNA expression and DNA methylation status can be further analyzed by quantitative (q) reverse transcription (RT)-PCR and methyl-DNA immunoprecipitation (MeDIP)-qPCR, respectively. Seven hundred twenty-six increased and 218 decreased H3K4me3 genes displaying significant H3K4me3 differences were found in uremia patients compared with healthy subjects. The results of ChIP-real-time PCR coincided well with microarray results. Expression analysis by qRT-PCR revealed positive correlations between mRNA and H3K4me3 levels. Aberrant DNA methylation can also be found on selected positive genes (CNOT1 PLTP EDG1 TCF3 KIR3DL2). In addition, we even found that there is an inverse relationship between H3K4me3 and promoter DNA methylation in uremia patients. Our studies indicate that there are significant alterations of H3K4me3 in uremia patients; these significant H3K4me3 candidates may help to explain the immunological disturbance and high cardiovascular complications in uremia patients. Such novel findings show the significance of H3K4me3 as a potential biomarker or promising target for epigenetic-based uremia therapies.
机译:表观基因组的研究对肾脏病学尤其是对尿毒症的兴趣很少。几项证据表明,尿毒症患者的基因组DNA低甲基化与心血管并发症之间存在联系。然而,迄今为止,我们对尿毒症中组蛋白甲基化改变的认识尚不清楚。使用染色质免疫沉淀微阵列(ChIP-chip)方法分析了20名尿毒症患者和20名健康受试者的外周血单个核细胞中的H3K4me3变异。 ChIP实时聚合酶链反应(PCR)用于验证微阵列结果。可以分别通过定量(q)逆转录(RT)-PCR和甲基-DNA免疫沉淀(MeDIP)-qPCR进一步分析mRNA表达和DNA甲基化状态。与健康受试者相比,在尿毒症患者中发现有726个H3K4me3基因增加和218个减少,显示出明显的H3K4me3差异。 ChIP实时PCR的结果与微阵列结果非常吻合。通过qRT-PCR进行的表达分析显示,mRNA与H3K4me3水平呈正相关。在选定的阳性基因(CNOT1 PLTP EDG1 TCF3 KIR3DL2)上也可以发现异常的DNA甲基化。此外,我们甚至发现尿毒症患者的H3K4me3与启动子DNA甲基化之间存在反比关系。我们的研究表明,尿毒症患者的H3K4me3有显着改变。这些重要的H3K4me3候选物可能有助于解释尿毒症患者的免疫功能紊乱和高心血管并发症。这样的新发现表明H3K4me3作为基于表观遗传学的尿毒症治疗的潜在生物标志物或有希望的靶标的重要性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号